[Treatment of accelerated arterial or malignant hypertension with captopril. Value, efficacy and outcome of visceral complications].
We have investigated 36 patients with accelerated or malignant hypertension (diastolic greater than 130 mm Hg and fundi at stage III or IV). The acute administration of Captopril 50 mg per os decreases the mean arterial pressure (MAP) by 20 p. cent during the 3 following hours. 30 patients have been treated from 1 to 9 months with Captopril (mean daily dose during first month = 212 mg) associated with Furosemide (mean daily dose = 80 mg) +/- beta blockers (11/30). The mean blood pressure in supine position under heavy conventional treatment was 205/121 mm Hg just before starting Captopril and was reduced to 156/90 mm Hg at the end of the first month of treatment. We observed a clear cut regression of fundi stages (III-IV to I-II) and cardiac or cerebral involvement, and a clearcut stabilization of the rapidly progressive chronic renal failure.
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005654:Fundus Oculi; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D006974:Hypertension, Malignant / Q000188:drug therapy; D006977:Hypertension, Renal / Q000188:drug therapy; D007668:Kidney / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D011247:Pregnancy; D011392:Proline / Q000031:analogs & derivatives*
D005665:Furosemide; D011392:Proline; D002216:Captopril
Le traitement de l'hypertension artérielle accélérée ou maligne par le captopril. Intérêt, efficacité et devenir des complications viscérales.